Strata Critical Co-CEO reports tax share withholding

Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine tax-related share disposition.

Rhea-AI Filing Summary

Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine tax-related share disposition. On March 8, 2026, 29,372 shares of Class A common stock were withheld at $4.54 per share to satisfy tax obligations from vesting restricted stock units. This was not an open-market sale but shares retained by the company to cover taxes. After this withholding, Tomkiel directly holds 1,613,990 shares of Class A common stock, indicating the transaction affected only a small portion of her overall position.

Insider Trade Summary

Exercise Price or Tax Liability: 29,372 shares

Exercise Price or Tax Liability 1 txn

Insider Tomkiel Melissa M.

Role Co-CEO and General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A common stock, $0.0001 par value per share	29,372	$4.54	$133K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,613,990 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Strata Critical Medical (SRTA) report for Melissa M. Tomkiel?

Strata Critical Medical reported that Melissa M. Tomkiel had 29,372 shares withheld to cover tax obligations from vesting restricted stock units. The disposition was coded as tax withholding, not an open-market sale, and reflects routine compensation-related activity.

Was the SRTA Form 4 transaction a sale of shares on the open market?

No, the Form 4 shows shares withheld by the issuer to satisfy tax withholding obligations. These 29,372 shares were used to pay taxes on vesting restricted stock units, rather than sold by the insider in an open-market transaction.

How many Strata Critical Medical shares does Melissa M. Tomkiel hold after this Form 4 event?

Following the tax-withholding transaction, Melissa M. Tomkiel directly holds 1,613,990 shares of Strata Critical Medical Class A common stock. This figure reflects her position after 29,372 shares were withheld by the issuer to cover tax obligations on RSU vesting.

What does transaction code "F" mean in the Strata Critical Medical (SRTA) Form 4?

Transaction code "F" indicates payment of an exercise price or tax liability by delivering securities. In this case, 29,372 SRTA shares were withheld by the company to satisfy tax withholding obligations arising from vesting restricted stock units granted as compensation.

What role does Melissa M. Tomkiel hold at Strata Critical Medical (SRTA)?

Melissa M. Tomkiel serves as both a director and an officer of Strata Critical Medical, holding the title of Co-CEO and General Counsel. The Form 4 reflects her compensation-related tax withholding transaction involving the company’s Class A common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 05:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	03/08/2026		F		29,372(1)	D	$4.54	1,613,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

	/s/ Melissa M. Tomkiel	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.